Verve Therapeutics Announces Development of Proprietary GalNAc-LNP Delivery Technology Enabling Efficient In Vivo Liver Delivery of Base Editors
Retrieved on:
Thursday, September 23, 2021
Blood, Therapy, Moyamoya disease, Gene editing, Apolipoprotein, Efficiency, RNA, Security (finance), N-Acetylgalactosamine, Private Securities Litigation Reform Act, Conference, U.S. Securities and Exchange Commission, Patient, Population, Gene, PCSK9, Company, Program, LDLR, Cardiovascular disease, Triglyceride, Delivery, Liver, Asialoglycoprotein, Research, Nasdaq, Track, GLOBE, Fine chemical, Vaccine, Copper
Verve is advancing a pipeline of single-course in vivo gene editing programs for the treatment of ASCVD indications, including HoFH.
Key Points:
- Verve is advancing a pipeline of single-course in vivo gene editing programs for the treatment of ASCVD indications, including HoFH.
- To overcome this, Verve has developed a novel approach that bypasses the LDLR and delivers LNPs to the liver through a different receptor.
- Asialoglycoprotein receptors (ASGPRs) are highly expressed in the liver with a high capacity to mediate uptake into the liver, independent of LDLR.
- To address this, we have designed and developed a proprietary GalNAc-LNP to enable efficient and potent liver editing regardless of LDLR expression.